Compare Royal Bank of Canada (RY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Royal Bank of Canada (RY) trades at $191.33, up 0.06% on the day, with a bearish technical signal and key support at $189. The company reported strong earnings, beating estimates for three consecutive quarters, with Q3 2026 EPS of $3.07 versus $2.89 expected. Revenue grew to $66.53B in 2025, and net income margin improved to 32.01%. Analyst sentiment is mixed, with 43% buy ratings but technical indicators showing selling pressure.

RY's outlook is supported by solid profitability and dividend payments, but faces risks from stretched valuations and negative cash flow trends. The stock's current bearish technical stance and high debt levels warrant caution, though institutional interest remains. Upside depends on sustained earnings growth and effective cost management amid economic uncertainties.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.